Ad
related to: clinical trials for neurogenic claudication treatment
Search results
Results from the WOW.Com Content Network
Diagnosis of neurogenic claudication is based on typical clinical features, the physical exam, and findings of spinal stenosis on computer tomography (CT) or X-ray imaging. [1] In addition to vascular claudication, diseases affecting the spine and musculoskeletal system should be considered in the differential diagnosis. [9]
Intermittent neurogenic claudication [17] [20] [21] characterized by lower limb numbness, weakness, diffuse or radicular leg pain associated with paresthesia (bilaterally), [20] weakness and/or heaviness in buttocks radiating into lower extremities with walking or prolonged standing. [17]
This may or may not correlate with the diagnosis of spinal stenosis which is based on clinical findings of radiculopathy, neurogenic claudication, weakness, bowel and bladder dysfunction, spasticity, motor weakness, hyperreflexia and muscular atrophy.
Magnesium deficiency causes neurogenic inflammation in a rat model. Researchers have theorized that since substance P which appears at day five of induced magnesium deficiency, is known to stimulate in turn the production of other inflammatory cytokines including IL-1, Interleukin 6 (IL-6), and TNF-alpha (TNFα), which begin a sharp rise at day 12, substance P is a key in the path from ...
Spinal or neurogenic claudication may be differentiated from arterial claudication based on activity and position. In neurogenic claudication, positional changes lead to increased stenosis (narrowing) of the spinal canal and compression of nerve roots and resultant lower extremity symptoms. Standing and extension of the spine narrows the spinal ...
However, research has shown that people show great reductions in vasovagal syncope through exposure-based exercises with therapists if the trigger is mental or emotional, e.g., sight of blood. [19] However, if the trigger is a specific drug, then avoidance is the only treatment.
Narrowing of the lumbar spinal canal causes a clinical condition known as neurogenic claudication, characterized by symptoms such as lower back pain, leg pain, leg numbness, and leg weakness that worsens with standing and walking and improves with sitting and lying down. [6]
ALTO-100, previously known as NSI-189 (NeuralStem Inc. 189), [3] is a drug described as a hippocampal neurogenesis stimulant and indirect brain-derived neurotrophic factor (BDNF) modulator which is under development for the treatment of major depressive disorder (MDD), bipolar depression, and post-traumatic stress disorder (PTSD).
Ad
related to: clinical trials for neurogenic claudication treatment